September 6, 2016
The German Cancer Research Center (DKFZ) is the foremost cancer research institute in Germany with key collaborations to enable personalized medicine for oncology. Illumina has been given access to talk to two of DKFZ’s leading experts to discuss the impact next-generation sequencing has had at DKFZ and its partner institute the National Center for Tumor Diseases (NCT).
Cancer is a disease that poses enormous challenges to research, because every cancer is different and its course can vary immensely even from one patient to the next. DKFZ is tasked with performing cancer research according to its statutes. It is the largest biomedical research institute in Germany and a member of the Helmholtz Association of National Research Centers. In 90 divisions and research groups, they have more than 1,200 scientists investigating the mechanisms of cancer, identifying cancer risk factors and are trying to find strategies to prevent people from getting cancer.
They are developing novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful, using the high throughput sequencing capabilities of the HiSeq X Ten System.
*Additional video courtesy of DKFZ.
